Sorrento Therapeutics subsidiary, Levena Biopharma Co., Ltd., has completed construction and began operations at its 25,000-sq.- ft. GMP manufacturing facility in Suzhou, China. The facility will be dedicated to supporting Sorrento’s antibody drug conjugate (ADC) pipeline and service business.  Sorrento currently has 12 preclinical cancer focused ADCs that are partnered with biopharma companies worldwide, under the Levena brand, including a HER2-targeting ADC, which has an expected IND ...